Uma Menon, MD
Neurology · New Orleans, LANPI 1629289319
Payments from drug & device makers
Across 95 payments — averaging $103.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$6K
- Neuropace, Inc.$1K
- AbbVie$1K
- SK Life Science, Inc.$344
- Sunovion Pharmaceuticals Inc.$334
- Greenwich Biosciences, Inc.$298
- plus $680 from 9 others
What the payments were for
- Consulting fees$4,52346%
- Travel & lodging$1,79918%
- Food & beverage$3,55136%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 38 | $5,661 |
| Neuropace, Inc. | 3 | $1,319 |
| AbbVie | 10 | $1,238 |
| SK Life Science, Inc. | 5 | $344 |
| Sunovion Pharmaceuticals Inc. | 9 | $334 |
| Greenwich Biosciences, Inc. | 6 | $298 |
| Eisai Inc. | 7 | $187 |
| Jazz Pharmaceuticals Inc. | 2 | $124 |
| Amgen | 8 | $122 |
| Novartis | 2 | $104 |
| Lilly USA, LLC | 1 | $78 |
| Livanova USA, Inc. | 1 | $18 |
| Neurelis, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,873 in reported general payments places this provider in the 65th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 38 | $1,723 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $292 |
| Lamotrigine | 11 | $144 |
Paid to pharmacies, not to this prescriber.
Other neurology in New Orleans
- Bridget BagertNew Orleans$1.4M
- Joseph TarsiaNew Orleans$1.2M
- Angela TraylorNew Orleans$941K
- Brian CopelandNew Orleans$304K
- John EnglandNew Orleans$268K
- Piotr OlejniczakNew Orleans$241K
- Sheryl Martin-SchildNew Orleans$106K
- Aimee AysenneNew Orleans$41K
- Caroline GoldinNew Orleans$38K
- Elizabeth CrabtreeNew Orleans$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.